Skip to main content
LDOS
NYSE Technology

Leidos Beats on Q3 EPS, Raises FY26 EPS Guidance to $12.50-$12.70

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: IT Services Stocks · Technology
Sentiment info
Positive
Importance info
7
Price
$143.9
Mkt Cap
$18.091B
52W Low
$98.86
52W High
$205.77
52W Position info
46% above low
Off High info
30% below high
Rel. Volume info
0.8× avg
Market data snapshot near publication time

LDOS sits 46% above its 52-week low of $98.86.

Summary

Leidos reported Q3 FY26 revenue of $4.63 billion (+4%) and non-GAAP EPS of $3.62 (+19%), then raised FY26 EPS guidance to $12.50-$12.70 while resetting revenue to $18.00-$18.20 billion for the SES joint venture deconsolidation.


Key Events · Earnings and Guidance · LDOS

  • Q3 Beat, EPS Guidance Raised

    Revenue of $4.63 billion rose 4% year-over-year and non-GAAP diluted EPS of $3.62 rose 19%. FY26 non-GAAP EPS guidance was lifted to $12.50-$12.70 from $12.20-$12.50.

  • Revenue Guide Cut on JV Deconsolidation

    FY26 revenue guidance moved to $18.00-$18.20 billion from $18.20-$18.40 billion after the October 5 SES joint venture close; organic revenue still grew 0.6% in the quarter.

  • Cash Generation and Capital Returns

    Q3 operating cash flow was $523 million and free cash flow $476 million; the company repurchased $504 million of stock and raised the quarterly dividend 4.7% to $0.45 per share.

  • Health Segment Drag Persists

    Health revenue fell 12% to $1.07 billion and operating margin dropped to 22.5% from 26.8% on managed health program volume declines.


Analysis · LDOS · Technology

Leidos beat on the bottom line and raised full-year EPS guidance for the third straight quarter, with non-GAAP EPS of $3.62 up 19% and free cash flow of $476 million. The revenue range came down to $18.00-$18.20 billion, but that is the arithmetic of deconsolidating the SES businesses into the Altaris joint venture closed October 5, not weaker demand — organic revenue still grew 0.6% and Homeland organic revenue rose 14.8%. The EPS raise and higher cash flow guide are the parts that move the thesis; the Health segment remains the soft spot, with revenue down 12% and margin down to 22.5%.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, LDOS was trading at $143.90 on NYSE in the Technology sector, with a market capitalization of approximately $18.1B. The 52-week trading range was $98.86 to $205.77. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

LDOS - Latest Insights

LDOS
Nov 03, 2026, 11:05 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $140.01
Real-time Price: $128.25 info
Change: -$11.76 (-8%) info
Market Cap: $15.646B info
LDOS
Nov 03, 2026, 6:00 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $143.90
Real-time Price: $128.25 info
Change: -$15.65 (-11%) info
Market Cap: $15.646B info
LDOS
Oct 13, 2026, 5:47 PM EDT
Source: Seeking Alpha
Importance Score:
7
Price at Filing: $119.70
Real-time Price: $128.25 info
Change: +$8.55 (+7%) info
Market Cap: $15.646B info
LDOS
Oct 05, 2026, 8:21 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $117.47
Real-time Price: $128.25 info
Change: +$10.78 (+9%) info
Market Cap: $15.646B info
LDOS
Oct 05, 2026, 8:09 AM EDT
Source: PR Newswire
Importance Score:
7
Price at Filing: $117.47
Real-time Price: $128.25 info
Change: +$10.78 (+9%) info
Market Cap: $15.646B info